Every Form 4 that OrthoPediatrics Corp. (KIDS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KIDS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KIDS filings page.
ORTHOPEDIATRICS CORP (KIDS) had a major shareholder, Squadron Capital LLC, report the sale of 302,369 shares of common stock on September 10, 2026, at a weighted average price of $21.01 per share, in multiple trades between $21.00 and $21.69. After this sale, Squadron Capital LLC reported holding 6,201,764 shares directly. The sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses, and no Rule 10b5-1 trading plan is reported. Squadron Capital Holdings LLC is the controlling member of Squadron Capital LLC.
ORTHOPEDIATRICS CORP (KIDS) reported that major shareholder Jennifer N. Pritzker, through Squadron Capital LLC, sold 302,369 shares of common stock on September 10, 2026 at a weighted average price of $21.01 per share, in multiple trades between $21.00 and $21.69. A separate line shows Pritzker holding 10,900 shares directly after the reported date. The sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses, and Pritzker expressly disclaims beneficial ownership of Squadron’s shares except to the extent of her pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) reports that on September 10, 2026, 302,369 shares of common stock were sold in the open market by Squadron Capital LLC, an entity associated with director and ten percent owner David R. Pelizzon, at a weighted average price of $21.01 per share (range $21.00–$21.69). Following this sale, Squadron is reported with 6,201,764 indirectly held shares, while Pelizzon also holds 44,384 shares directly, including 17,959 restricted stock awards; he disclaims beneficial ownership of Squadron’s shares except to the extent of his pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) had a Form 4 filed for a large shareholder, Squadron Capital LLC, reporting a sale of 22,500 shares of Common Stock on September 2, 2026, at a weighted average price of $23.35 per share, in transactions ranging from $23.01 to $23.74. After this sale, Squadron Capital LLC reports holding 6,504,133 shares, which it holds directly, while Squadron Capital Holdings LLC is described as its controlling member. No Rule 10b5-1 trading plan is reported for this transaction, and a footnote states the sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses.
ORTHOPEDIATRICS CORP (KIDS) reported that on September 2, 2026, an entity associated with 10% owner Jennifer N. Pritzker, Squadron Capital LLC, sold 22,500 shares of common stock in a sale reported as an open market or private transaction at a weighted average price of $23.35 per share, with individual trade prices ranging from $23.01 to $23.74. The filing states this sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses and that no Rule 10b5-1 trading plan is reported.
After the reported transaction, Jennifer N. Pritzker is shown as holding 10,900 shares directly, and additional shares are held indirectly through Squadron Capital LLC, the Tawani Foundation, the Pritzker Military Foundation, the reporting person's spouse, and the Pritzker Military Museum and Library. For each of these indirect positions, she may be deemed the beneficial owner but expressly disclaims beneficial ownership of the shares, except to the extent of her pecuniary interest in them.
ORTHOPEDIATRICS CORP (KIDS) reported that director and ten percent owner David R. Pelizzon, through affiliated entity Squadron Capital LLC, indirectly sold 22,500 shares of common stock on September 2, 2026 at a weighted average price of $23.35 per share. The sale was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses. After this transaction, entities associated with Pelizzon held 6,504,133 indirect shares and he held 44,384 shares directly, including 17,959 restricted stock awards, while he expressly disclaims beneficial ownership of Squadron’s shares except to the extent of his pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) reported that Squadron Capital LLC, a ten percent owner, sold a total of 336,831 shares of common stock in two open-market transactions. On August 28, 2026 it sold 326,700 shares at a weighted average price of $23.04 per share, with individual prices ranging from $23.00 to $23.82. On September 1, 2026 it sold 10,131 shares at a weighted average price of $23.10, with individual prices ranging from $23.00 to $23.58. The footnotes state the sale by Squadron Capital LLC was undertaken to provide additional capital for its other portfolio businesses, and that Squadron Capital Holdings LLC is the controlling member of Squadron Capital LLC.
ORTHOPEDIATRICS CORP (KIDS) reported insider activity by ten percent owner Jennifer N. Pritzker, relating primarily to sales by Squadron Capital LLC, an entity with which she is associated. Squadron sold 326,700 shares of common stock on August 28, 2026 at a weighted average price of $23.04 per share (individual trades ranged from $23.00–$23.82), and later sold 10,131 shares on September 1, 2026 at a weighted average price of $23.10 (trades from $23.00–$23.58). The filing shows a separate direct holding of 10,900 shares of common stock for the reporting person as of August 28, 2026. For the indirect holdings, the reporting person may be deemed a beneficial owner through Squadron and several related foundations and entities but expressly disclaims beneficial ownership except to the extent of her pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) insider reporting person David R. Pelizzon, a director and ten percent owner, reported indirect sales of Orthopediatrics common stock carried out by Squadron Capital LLC. Squadron sold a total of 336,831 shares on August 28 and September 1, 2026 at weighted average prices in the low‑$23 range, with prices ranging from $23.00 to about $23.82. Pelizzon is President and a member of Squadron’s Managing Committee and may be deemed a beneficial owner of these indirectly held shares, but he expressly disclaims beneficial ownership except to the extent of his pecuniary interest. He also reports 44,384 shares of common stock held directly, including 17,959 restricted stock awards.
ORTHOPEDIATRICS CORP (KIDS) reported that Jennifer N. Pritzker, a ten percent owner, filed a Form 4 showing indirect sales of an aggregate 38,300 shares of common stock on August 24–26, 2026. The sales were executed by Squadron Capital LLC, a manager-managed LLC, at weighted average prices around the mid-$20s per share, with detailed price ranges disclosed in footnotes. Pritzker reports 10,900 shares held directly and disclaims beneficial ownership of the indirectly held shares except to the extent of her pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) reported insider activity by large shareholder entities Squadron Capital LLC and Squadron Capital Holdings LLC. Squadron Capital LLC sold a total of 38,300 shares of Common Stock over August 24–26, 2026 in open-market transactions at weighted-average prices between about $24.13 and $25.82 per share. The filing states the sales were undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses. The shares are held directly by Squadron Capital LLC, and Squadron Capital Holdings LLC is its controlling member.
ORTHOPEDIATRICS CORP (KIDS) received a Form 4 from director and ten percent owner David R. Pelizzon reporting sales of common stock held indirectly through Squadron Capital LLC. On 2026-08-24, 2026-08-25, and 2026-08-26, Squadron sold a total of 38,300 shares of Orthopediatrics common stock in open-market or private transactions at weighted average prices reported as $25.75, $24.74, and $24.28 per share, each with detailed price ranges provided in footnotes. A separate entry shows Pelizzon holding 44,384 shares directly as of 2026-08-24, including 17,959 restricted stock shares. Footnotes state the sales were undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses and that Pelizzon may be deemed a beneficial owner through his role at Squadron but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
Pelizzon David R reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director David R. Pelizzon received an award of 11,436 shares of common stock on June 9, 2026. The shares were granted at no cost as a stock award, increasing his direct holdings to 44,384 common shares, including 17,959 restricted stock awards.
The filing also reports 6,901,764 common shares held indirectly through Squadron Capital LLC. As President and a member of Squadron’s Managing Committee, Pelizzon may be deemed a beneficial owner, but he expressly disclaims beneficial ownership except for his pecuniary interest.
OrthoPediatrics Corp director Bryan W. Hughes received a stock award of 11,436 shares of common stock. The shares were granted at no cash cost as equity compensation, rather than bought on the open market. After this award, his direct holdings total 32,663 shares.
A footnote explains that these holdings include restricted stock awards totaling 17,959 shares, which typically vest over time subject to conditions. The filing reports only this grant transaction and does not show any share sales or option exercises.
ORTHOPEDIATRICS CORP director Kelly Laine Fischer received a stock-based compensation grant. On June 9, 2026, Fischer was awarded 11,436 shares of Common Stock at $0.00 per share, reported as a grant or other acquisition rather than an open-market purchase.
Following this award, Fischer’s directly held position totals 15,781 shares, which the filing notes includes restricted stock awards. The transaction reflects routine equity compensation for a director and does not represent a discretionary market trade in the company’s shares.
Riccitelli Samuel D reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP director Samuel D. Riccitelli received a stock grant of 11,436 shares of Common Stock. The award was granted at no cash cost per share and is held directly. Following this grant, he directly owns 31,859 shares, including restricted stock awards totaling 17,959 shares.
Ruf Harold reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director Harold Ruf reported a stock award of 11,436 shares of common stock. The award was granted at a price of $0.00 per share as equity compensation, not an open-market purchase.
Following the grant, Ruf directly holds 19,837 shares of common stock. The filing also reports indirect holdings of 2,400 shares through The Last Chance Legacy Trust and 19,247 shares through the Harald Ruf Roth IRA, where he is deemed to have a pecuniary interest under Section 16 regulations. Certain positions include restricted stock awards noted in the footnotes.
Bailey David R reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP President and CEO David R. Bailey received a grant of 119,140 shares of Common Stock on June 9, 2026. The award was reported at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase.
Following this grant, Bailey directly holds 417,160 shares of the company’s Common Stock. The holdings include restricted stock awards totaling 307,031 shares, which typically vest over time and are subject to continued service or performance conditions.
OrthoPediatrics Corp director Jimmy Duane McDonald received a stock grant. On June 9, 2026, he acquired 11,436 shares of common stock as a grant or award at a stated price of $0.00 per share, bringing his direct holdings to 24,568 shares, including 17,959 restricted stock awards.
Infante (Reynolds) Marie C reported acquisition or exercise transactions in this Form 4 filing.
OrthoPediatrics Corp director Marie C. Infante received an equity grant of 11,436 shares of common stock on June 9, 2026. The shares were awarded at a price of $0.00 per share, indicating a compensation-related stock award rather than an open-market purchase.
Following this grant, Infante directly holds 31,202 shares of OrthoPediatrics common stock. A footnote explains that this total includes restricted stock awards totaling 17,959 shares, which are typically subject to vesting or service conditions.
Throdahl Mark C reported acquisition or exercise transactions in this Form 4 filing.
ORTHOPEDIATRICS CORP director Mark C. Throdahl reported a stock award and updated share holdings. He received a grant of 11,436 shares of common stock at no cost, bringing his direct ownership to 179,317 shares, which includes 38,660 restricted stock awards.
He also reported 22,497 shares held indirectly through a trust. These entries reflect compensation-related equity awards and the current size of his direct and indirect positions, rather than open‑market buying or selling.
ORTHOPEDIATRICS CORP director George Sinclair Mitchell Dyer received an equity grant of 11,436 shares of Common Stock on June 9, 2026. The shares were acquired at no stated purchase price as a grant or award and increased his direct holdings to 24,568 shares. A footnote states that this total includes restricted stock awards of 17,959 shares, indicating a significant portion of his position is subject to vesting or other restrictions as part of his compensation.
OrthoPediatrics Corp General Counsel and Secretary Daniel J. Gerritzen transferred 2,479 shares of Common Stock as a bona fide gift. The shares were given without receiving any payment. After the gift, he directly holds 147,054 shares, which the disclosure states include 121,054 restricted stock awards.
ORTHOPEDIATRICS CORP executive Joseph W. Hauser reported a stock grant and related tax sale. He acquired 65,700 shares of Common Stock on March 15, 2026 as a grant at $0.00 per share, increasing his direct holdings to 203,363 shares.
On March 16, 2026, 8,596 shares were sold at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares. After these transactions, he directly owned 194,767 shares of Common Stock, including restricted stock awards totaling 155,805 shares.
OrthoPediatrics Corp executive Fred Hite, the COO and CFO, reported both a stock grant and a related share sale. On March 15, 2026, he acquired 77,405 shares of Common Stock as a grant at $0.00 per share. On March 16, 2026, he sold 12,993 shares of Common Stock at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares.
After these transactions, Hite directly owned 277,477 shares of OrthoPediatrics Common Stock, which the disclosure states includes restricted stock awards totaling 197,765 shares.
OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations triggered when restricted stock vested, rather than as a discretionary portfolio move.
After this transaction, Bailey directly holds 298,020 shares of OrthoPediatrics common stock, which includes 187,891 shares of restricted stock awards. The sale represents only a portion of his overall equity position in the company.
OrthoPediatrics Corp President of Scoliosis Gregory A. Odle reported a stock compensation event combined with a tax-related share sale. He received a grant of 47,380 shares of common stock as a restricted stock award. The next day, 8,433 shares were sold specifically to satisfy tax withholding obligations upon vesting of restricted shares, according to the footnote. After these transactions, he directly holds 187,735 shares of common stock, which the disclosure states includes restricted stock awards totaling 121,054 shares.
OrthoPediatrics Corp General Counsel Daniel J. Gerritzen reported compensation-related stock activity. On March 15, he acquired 47,380 shares of common stock as a grant or award at $0.00 per share. On March 16, he sold 8,614 shares at $17.25 per share.
According to a footnote, the shares sold on March 16 were used to satisfy tax-withholding obligations tied to the vesting of restricted shares, rather than a discretionary sale. After these transactions, he directly holds 149,533 shares of common stock, which includes restricted stock awards totaling 121,054 shares.